ATA3219: Off-the-Shelf Allogeneic CD19 Program for B-Cell Malignancies Built on Our EBV T-Cell Platform

    • Academic program generated a proof-of-principle for EBV T-cell platform demonstrating the potential to generate off-the-shelf, allogeneic CAR T immunotherapies.
    • ATA3219: Atara's next-generation, off-the-shelf, allogeneic EBV+ CD19-1XX CAR T-cell immunotherapy containing a modified CD3z signaling domain, 1XX.
Curran KJ, Sauter CS, Kernan NA, et al. Durable remission following “Off-the-Shelf” Chimeric Antigen Receptor (CAR) T-cells in patients with relapse/refractory (R/R) B-cell malignancies. Biol Blood Marrow Transplant. 2020;26(3):S89. IND = Investigational New Drug


Allogeneic CAR T targeting CD19, currently in clinical development, leverages our EBV T-cell platform and features a next-generation 1XX co-stimulatory domain.

  • ATA3219: B-cell malignancies
    Phase 1

Next-Generation CAR T Technology

Our preclinical pipeline is rapidly expanding with novel technologies and next-generation, multi-targeted CAR T immunotherapies thanks to our collaborations with Moffitt Cancer Center and Memorial Sloan Kettering Cancer Center.